April 21, 2016, Kitchener, Ontario
Posted by: Robert Deutschmann, Personal Injury Lawyer
There is some interesting new hope for sufferers of chronic TBI. SanBIO has announced that they are staring the world’s first phase 2 trials of treatment for TBI will stem cells. The trials, in Japan, will be on 52 patients. The drug SB623 is a regenerative cell medicine. It has been shown to improve outcomes in patients with ischemic stroke who have persistent motor deficits. These new trials will be on patients with TNI.
The stem cells are derived from bone marrow harvested from healthy adults and it works in neural tissue by promoting triggering the brain’s natural regenerative ability.
Hopes are high for the new drug. You can read about the company and the cell therapy on their website.
|